Unversity of Connecticut Health Center
Farmington, Connecticut, 06030, United States
NCT Number: NCT00802321
To monitor the inhibition of 5a-reductase (5AR) enzyme activity at 1, 3, 7, 14, 21, 28 and 42 days following administration of a single dose of dutasteride (2, 3, or 4 mg) by measuring the change in blood levels of 3a-androstanediol glucuronide (3a-diolG) and the ratio of dihydrotestosterone (DHT) to testosterone. To accomplish this aim, an open-label, between-subjects dose comparison study design will be employed with subjects receiving a 2, 3, or 4 mg dosage. Subjects (up to n=40 enrolled to allow a minimum of 24 completers) will be randomly assigned to one of the 3 dose levels. Results of this study will inform the dose selection for a subsequent placebo-controlled, within-subject, crossover study of dutasteride on the effects of alcohol.
A secondary aim of this study is to examine the correlation of a genetic variation in the type I 5AR gene and baseline DHT/T ratio and effect of dutasteride at day 3. A variation in this gene which is one of the targets of dutasteride has been reported to be associated with higher baseline levels of DHT.
Looking for future studies?
Notify Me21 year–55 year
Male
Interventional
Not applicable
Farmington, Connecticut, 06030, United States
Alcohol abuse and dependence remain important public health problems. The chemical mechanisms by which alcohol affects the nervous system are not well understood. Recent theories suggest that alcohol stimulates release of "neuroactive" steroid hormones which are important mediators of alcohol effects. This proposal seeks to identify the most appropriate dosage of an FDA approved medication, dutasteride, which blocks the metabolism of steroid hormones, so that we can use dutasteride as a pharmacologic probe of the biochemistry of alcohol effects in human subjects in a subsequent study.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects will receive a single dose of 2, 3 or 4 mg of dutasteride based on random assignment.
Other names: Avodart
Time frame: 1-42 days
Time frame: 1-42 days
UConn Health
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00734656
Alcohol Abuse, Alcohol Related Disorders
Farmington, Connecticut, United States
View Trial DetailsNCT02407340
Alcohol Related Disorders, Alcohol Withdrawal Delirium
Baltimore, Maryland, United States
View Trial DetailsNCT00202514
Alcohol Related Disorders, Alcohol-Related Disorders
Seattle, Washington, United States
View Trial DetailsNCT01655615
Alcohol Related Disorders, Alcohol-Related Disorders
Montreal, Quebec, Canada
View Trial Details